Dr. Mark Onaitis
Thoracic Surgeon, UC San Diego HealthDr. Mark Onaitis is a board-certified thoracic surgeon and professor of surgery at Moores Cancer Center at UC San Diego Health in California. He has experience in malignant and benign conditions, including mesothelioma, lung cancer and esophageal cancer.
-
Expertise:Clinical Research
Robotics
Science Research
Thoracoscopy -
Certifications:American Board of Thoracic Surgery
California State Medical License
Thoracic and Cardiac Surgery -
Speciality:Esophageal Cancer Treatment
Esophageal Disorder Treatment
Gastroesophageal Reflux Disease (GERD) Treatment
Heart Valve Program
Lung Cancer Surgery
Mesothelioma Treatment
Myasthenia Gravis Treatment
Thoracic Surgery
Thymus Cancer Treatment -
Gender:Male -
Language:English
About Dr. Mark Onaitis
Dr. Mark Onaitis completed his fellowship in thoracic surgery and a residency in general surgery at Duke University School of Medicine. While at Duke, Onaitis served as chief resident before earning a medical degree. He also received a master’s degree in clinical research from Duke University.
At Moores Cancer Center at UC San Diego Health in California, Onaitis specializes in malignant and benign chest conditions such as lung cancer, esophageal cancer, achalasia, gastroesophageal reflux, hiatal hernia, myasthenia gravis and thymic malignancy. He utilizes minimally invasive techniques, including thoracoscopy and robotics, to treat conditions.
Onaitis is a professor in the department of surgery at the University of California San Diego School of Medicine where he trains medical students, residents and fellows. He also has an interest in science research in stem and progenitor cells and lung cancer. Onaitis’s clinical research focuses on quality indicators in thoracic surgery.
He is a member of the American College of Surgeons, the Society of Thoracic Surgeons and the American Association of Thoracic Surgeons. As well as being the author of several published medical articles, he is also a reviewer for multiple professional journals.
Dr. Onaitis’s Role as an Expert Contributor on Asbestos.com
Onaitis’s experience spans more than two decades in thoracic surgery making him a mesothelioma specialist. His training with top mesothelioma experts and years of operating experience make him an ideal medical reviewer for The Mesothelioma Center at Asbestos.com, the nation’s most trusted mesothelioma resource.
He confirms the information on many of the medical pages on Asbestos.com meet current professional standards concerning diagnosis and treatment of mesothelioma and lung cancer.
Specialties of Dr. Mark Onaitis
- Cancer
- Cardiothoracic Surgery
- Minimally Invasive Surgery
- Thoracic Surgery
Experience and Medical Education
- University of California in San Diego
- Duke University School of Medicine (Fellowship)
- Duke University School of Medicine (Residency)
- Duke University School of Medicine (M.D.)
Awards and Recognition
- Chancellor’s Clinical Leadership in Academic Medicine Program 2010
- Alpha Omega Alpha 2003
- Weck Outstanding Basic Surgery Research Award 2001
Dr. Mark Onaitis’s Publications
- Onaitis, M. et al. (2022, May). Single-cell chromatin profiling of the primitive gut tube reveals regulatory dynamics underlying lineage fate decisions. Nature Communications.
- Onaitis, M. et al. (2018, July). Transcriptional signature primes human oral mucosa for rapid wound healing. Science Translational Medicine.
- Onaitis, M. et al. (2018, May). Minimally Invasive Lung Cancer Surgery Performed by Thoracic Surgeons as Effective as Thoracotomy. Journal of Clinical Oncology.
- Onaitis, M. et al. (2016, June). Longitudinal Follow-up of Lung Cancer Resection From the Society of Thoracic Surgeons General Thoracic Surgery Database in Patients 65 Years and Older. The Annals of Thoracic Surgery.
- Onaitis, M. et al. (2013, March). Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell Stem Cell.
Watch Our Free Mesothelioma Webinars
Find Active Mesothelioma Clinical Trials
Mesothelioma Trust Funds
